PT  - JOURNAL ARTICLE
AU  - YUN, CHUL WON
AU  - LEE, JUN HEE
AU  - LEE, SANG HUN
TI  - Casein Kinase 2α Augments Oxaliplatin Resistance in Colorectal Cancer Cells by Increasing ABCE1 Expression
AID  - 10.21873/anticanres.16419
DP  - 2023 Jun 01
TA  - Anticancer Research
PG  - 2519--2525
VI  - 43
IP  - 6
4099  - http://ar.iiarjournals.org/content/43/6/2519.short
4100  - http://ar.iiarjournals.org/content/43/6/2519.full
SO  - Anticancer Res2023 Jun 01; 43
AB  - Background/Aim: Antitumor drug resistance is a major hurdle in treating patients with malignant tumors. Casein kinase 2α (CK2α) expression is highly enhanced in oxaliplatin-resistant CRC cells. We investigated whether CK2α expression is associated with oxaliplatin resistance in CRC cells. Materials and Methods: To determine the effect of CK2α on drug resistance in CRC, we assessed the cell viability, adenosine triphosphate-binding cassette (ABC) transporter expression, apoptosis, and sphere formation according to CK2α expression in oxaliplatin-resistant CRC cells. Results: CK2α expression was significantly increased in oxaliplatin-resistant CRC cells compared with that in wild-type CRC cells. In addition, the mRNA expression of ABC transporters, including ABCA12, ABCC2, and ABCE1, was significantly enhanced in oxaliplatin-resistant CRC cells, whereas this effect was blocked by the knockdown of CK2α. Furthermore, a cell viability test showed that oxaliplatin resistance was inhibited by decreasing CK2α expression, resulting in the induction of apoptosis and suppression of sphere formation. Conclusion: CK2α regulates cell survival, apoptosis, sphere formation, and drug resistance in oxaliplatin-resistant CRC cells by regulating ABC transporters. Therefore, targeting CK2α in drug-resistant CRC cells may be a novel strategy for treating patients with CRC.